Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.78 |
| ▸ | CDK2 | P24941 | 2/20 | 0.78 |
| ▸ | KDR | P35968 | 5/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583253 | 1.00 | CDK1 (0.78) | CDK1CDK2KDRCHEK1NPC1 | |
| SCHEMBL6969778 | 0.88 | CDK1 (1.00) | CDK1CDK2KDRCHEK1NPC1 | |
| SCHEMBL29644972 | 0.88 | CDK1 (1.00) | CDK1CDK2KDRCHEK1NPC1 | |
| SCHEMBL8063320 | 0.87 | NPC1 (0.65) | CDK1CDK2KDRCHEK1NPC1 | |
| Methane SCHEMBL8064257 | 0.85 | NPC1 (0.64) | CDK1CDK2KDRCHEK1NPC1 | |
| SCHEMBL11867321 | 0.84 | CDK1 (0.57) | CDK1CDK2KDRCHEK1NPC1 | |
| SCHEMBL11856153 | 0.84 | KDR (0.61) | CDK1CDK2KDRCHEK1GSR | |
| SCHEMBL11865843 | 0.84 | KDR (0.60) | CDK1CDK2KDRCHEK1GSR | |
| SCHEMBL11861276 | 0.84 | KDR (0.60) | CDK1CDK2KDRCHEK1GSR | |
| SCHEMBL7089501 | 0.84 | KDR (0.60) | CDK1CDK2KDRCHEK1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-3932430-A | Substituted indeno, naphtho and cyclohepta pyrazoles | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1G1, CSNK1A1, CSNK1D | CDK1 36/4885CDK2 82/4885KDR 4748/4885 |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | CDK1 31/4885CDK2 77/4885KDR 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.